| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $684K | — | +38.7% |
| SG&A Expense | $1.0M | — | +30.1% |
| Operating Income | -$1.7M | — | -33.5% |
| Net Income | -$1.7M | — | -31.1% |
| EPS (Basic) | -$0.08 | — | +0.0% |
| EPS (Diluted) | -$0.08 | — | +0.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3.7M | -18.2% | +1.6% |
| Current Assets | $4.4M | -17.5% | -26.6% |
| Total Assets | $5.7M | -12.2% | -27.6% |
| Current Liabilities | $431K | +116.6% | -46.5% |
| Stockholders' Equity | $5.3M | -16.2% | -25.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.0M | — | -45.1% |
| Financing Cash Flow | $220K | — | -92.8% |